- Report
- April 2024
- 135 Pages
Asia Pacific
From €1366EUR$1,500USD£1,185GBP
- Report
- February 2022
- 50 Pages
Global
From €3187EUR$3,500USD£2,765GBP
- Drug Pipelines
- March 2021
Global
From €1821EUR$2,000USD£1,580GBP
- Drug Pipelines
- July 2020
- 61 Pages
Global
From €3187EUR$3,500USD£2,765GBP
- Report
- August 2022
United States
From €1767EUR$1,940USD£1,533GBP
- Report
- August 2022
Global
From €719EUR$790USD£624GBP
- Report
- August 2021
Europe
From €3114EUR$3,420USD£2,702GBP
- Report
- August 2021
Global
From €3633EUR$3,990USD£3,152GBP
- Report
- December 2023
- 182 Pages
Global
€4549EUR$4,995USD£3,946GBP
- Report
- February 2022
- 94 Pages
Global
From €3200EUR$3,764USD£2,873GBP
- Report
- October 2022
- 94 Pages
Global
From €1821EUR$2,000USD£1,580GBP
- Report
- November 2021
- 844 Pages
Global
From €4553EUR$5,000USD£3,950GBP
- Report
- December 2023
- 279 Pages
Global
From €3360EUR$3,690USD£2,915GBP
- Report
- May 2023
- 258 Pages
Global
From €3251EUR$3,570USD£2,820GBP
- Book
- April 2020
- 638 Pages
- Book
- April 2020
- 454 Pages
Diabetic Neuropathy is a type of nerve damage caused by diabetes. It is a common complication of diabetes, affecting up to 70% of people with the condition. Symptoms of diabetic neuropathy can include pain, numbness, tingling, and loss of sensation in the feet, legs, and hands. It can also cause problems with balance and coordination, as well as digestive issues. Endocrinologists are medical professionals who specialize in the diagnosis and treatment of endocrine disorders, including diabetes. They are well-equipped to diagnose and treat diabetic neuropathy, as well as provide lifestyle advice to help manage the condition.
Companies in the Diabetic Neuropathy market include Novartis, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more
